Chroma Medicine
@chromamedicine
Followers
1K
Following
93
Media
143
Statuses
180
Pioneering a new class of genomic medicines that harness epigenetics to deliver new treatments for patients with serious diseases
Boston, MA
Joined October 2021
Celebrating a transformative milestone as the exceptional teams at Chroma Medicine + Nvelop Therapeutics unite to form nChroma Bio. Together, we are embarking on a shared mission to redefine the future of genetic medicines. Stay tuned for what’s next + follow: @nChromaBio.
We’re thrilled to announce the launch of nChroma Bio today, formed through the strategic merger of @chromamedicine and @nvelop_tx , to pioneer a new class of genetic medicines.
0
2
12
Join us at the 5th Annual Genome Editing Therapeutics Summit where @ShaneWrightBME, MS, Scientist I, Platform Technologies, will discuss platform optimization through our PCSK9-EE, translation into an #HBV therapeutic (CRMA-1001) + more. #EpigeneticEditing
0
0
2
Cheers to 3 years since launch! Celebrating the cutting-edge science, passionate team, and trusted investors fueling us as we work to shape the future of #GeneRegulation and revolutionize the treatment of disease with single-course #EpigeneticEditing therapeutics. Thank you team!
1
1
3
RT @jaffeab: Nice piece about the data presented by @chromamedicine colleague, X-less Yesse Angleró-Rodríguez, @HepBFoundation Internationa….
0
1
0
We presented new preclinical data at the @HepBFoundation 2024 Int’l HBV Meeting demonstrating durable, dose-dependent suppression of hepatitis B surface antigen expression in vivo achieved with a single dose of CRMA-1001. Read more: #HBV2024 #Biotech
1
0
2
We’re heading to the Windy City for the @HepBFoundation 2024 International HBV Meeting where we’ll share new preclinical data supporting CRMA-1001, our investigational #EpigeneticEditing drug for the treatment of chronic hepatitis B. More: . #HBV2024
0
0
1
London calling! Yesterday at @escardio Congress 2024, we shared preclinical data showcasing the best-in-class potency of our efficient + durable PCSK9-targeted #EpigeneticEditor. More: #ESCCongress2024
0
0
6
We are excited to share new data highlighting the potency of our #EpigeneticEditors targeting #PCSK9. Frederic Tremblay, PhD, will be presenting at the @escardio 2024 Congress in London in September. For more information: #ESCCongress2024.#biotech
0
1
4
Thank you @Labiotech_eu and Roohi Mariam Peter for showcasing our novel approach to #EpigeneticEditing including our recent partnership with the Whitehead Institute to exclusively license their #CHARM technology. Read more here: #Biotech.
0
0
3
Honoring #WorldHepatitisDay – Hepatitis is a major public health challenge impacting over 300M people. #HBV can cause severe liver disease + cancer. We are dedicated to advancing our #EpigeneticEditing technology to drive functional cure of HBV.
0
0
1
Chroma welcomes Melissa J Moore, PhD, to our Board of Directors. Moore brings decades of experience directing RNA research and drug development at leading pharma companies and in academia. We are delighted to have her on #TeamChroma!. Read more:
0
0
6
Congratulations to @NoahGood on his well-deserved promotion to Chief Business Officer!. Noah’s leadership and deep experience in life sciences #BusinessDevelopment have been instrumental to our growth, and we are proud to have him on #TeamChroma. #Biotech
0
1
4
Great update here by @JasonMMast to the incredibly moving story of Sonia and Eric’s work in @JswLab. We are proud to be included in the article and have exclusively licensed CHARM.
0
0
4
Check out this exciting new technology, CHARM, that we will leverage through an exclusive license with @WhiteheadInst as we work to advance durable #EpigeneticEditing therapies to patients. 👇.
.@JswLab and @broadinstitute collaborators have developed a gene-silencing tool that shows promise as a therapy against fatal prion diseases. The tool, called CHARM, paves the way for a new class of genetic approaches to treat certain diseases:
0
1
6
Today we are excited to announce the expansion of our #EpigeneticEditing capabilities via an exclusive license agreement with @WhiteheadInst to access CHARM, a novel technology developed in the lab of Chroma co-founder Jonathan Weissman. More:
1
3
15
Today at #EASLCongress 2024, Yesseinia Angleró-Rodríguez, PhD, presented preclinical data supporting the potential of our #EpigeneticEditors to drive functional cure for #HBV via efficient, durable, and specific silencing. See the presentation here:
0
2
5
Ciao, Milano! Join us tomorrow at the @EASLnews 2024 Congress, as Yesseinia Angleró-Rodríguez, PhD, shares new preclinical data showcasing the potential of our #EpigeneticEditing therapeutics to repress #HBV. Abstract: #EASLCongress
0
0
1
Yesseinia Angleró-Rodríguez, PhD, will be heading to Milan for the @EASLNews 2024 Congress to present new preclinical data highlighting efficient, specific, and durable silencing of #HBV using our #EpigeneticEditors. Read our abstract: #EASLCongress
0
2
9
Chroma welcomes Jenny Marlowe, PhD, to #TeamChroma as Chief Development Officer. Jenny brings 15+ years of scientific and leadership experience in translational, preclinical development, and preclinical safety. #ClinicalDevelopment.#EpigeneticEditing
0
1
10
#ASGCT2024: Jamie Schafer highlights 5-locus multiplexing in T cells. Epigenetic editing’s unique multiplexibility may help streamline manufacturing and reduce genotoxic risk for highly engineered #CellTherapies. #ASGCT24 #EpigeneticEditing #Biotech
0
0
14